文献速递生殖医学

胚胎移植后SARS-CoV-2感染与体外受精早期妊娠结局的关联:一项前瞻性队列研究

The association of post-embryo transfer SARS-CoV-2 infection with early pregnancy outcomes in in vitro fertilization: a prospective cohort study.
PubMed 文献 · Am J Obstet Gynecol · 2023-12-20

该前瞻性队列研究在中国一家公立体外受精中心纳入2022年9月至12月接受体外受精/卵胞浆内单精子注射治疗、年龄20至39岁、体重指数18至30 kg/m2的女性患者,随访至2023年3月,分析胚胎移植后10周内SARS-CoV-2感染与早期妊娠结局的关联。结果显示,移植后14天内感染与生化妊娠率、28天内感染与着床率和临床妊娠率、10周内感染与早期流产率均无显著负相关。

要点

  • 移植后14天内SARS-CoV-2感染与生化妊娠率无显著负相关(调整OR 0.74,95%CI 0.51-1.09)。
  • 移植后28天内感染组着床率36.6% vs 未感染组44.0%(P=.181),无显著关联。
  • 移植后10周内感染与早期流产率无显著关联(调整OR 0.77,95%CI 0.35-1.71)。

核心结论

  • 研究提示胚胎移植后10周内SARS-CoV-2感染可能与体外受精/卵胞浆内单精子注射患者的生化妊娠率、着床率、临床妊娠率和早期流产率无负相关。
  • 该结论仅适用于年龄20至39岁、既往无SARS-CoV-2感染、体重指数18至30 kg/m2的目标人群。

研究设计与样本

  • 前瞻性队列研究,在中国一家公立体外受精中心开展。
  • 纳入2022年9月至2022年12月接受体外受精/卵胞浆内单精子注射治疗、年龄20至39岁、体重指数18至30 kg/m2的女性患者,随访至2023年3月。
  • 共分析857例女性患者,追踪移植后≤14天、≤28天和≤10周的SARS-CoV-2感染时间、症状、疫苗接种状态、疫苗接种与胚胎移植间隔及早期妊娠结局。
  • 采用单因素分析和多因素logistic回归分析感染状态等因素与早期妊娠结局的关联。

主要发现

  • 移植后14天内SARS-CoV-2感染与生化妊娠率无显著负相关(调整OR 0.74,95%CI 0.51-1.09)。
  • 移植后28天内感染组着床率36.6% vs 未感染组44.0%(P=.181),无显著关联。
  • 调整混杂因素后,移植后28天内感染与临床妊娠率无统计学显著关联(调整OR 0.69,95%CI 0.56-1.09)。
  • 移植后10周内感染与早期流产率无显著关联(调整OR 0.77,95%CI 0.35-1.71)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The influence of SARS-CoV-2 infection after embryo transfer on early pregnancy outcomes in in vitro fertilization or intracytoplasmic sperm injection-embryo transfer treatment remains inadequately understood. This knowledge gap endures despite an abundance of studies investigating the repercussions of preceding SARS-CoV-2 infection on early pregnancy outcomes in spontaneous pregnancies. OBJECTIVE: This study aimed to investigate the association between SARS-CoV-2 infection within 10 weeks after embryo transfer and early pregnancy outcomes in patients undergoing in vitro fertilization/intracytoplasmic sperm injection treatment. STUDY DESIGN: This prospective cohort study was conducted at a single public in vitro fertilization center in China. Female patients aged 20 to 39 years, with a body mass index ranging from 18 to 30 kg/m2, undergoing in vitro fertilization/intracytoplasmic sperm injection treatment, were enrolled between September 2022 and December 2022, with follow-up extended until March 2023. The study tracked SARS-CoV-2 infection time (≤14 days, ≤28 days, and ≤10 weeks after embryo transfer), symptoms, vaccination status, the interval between vaccination and embryo transfer, and early pregnancy outcomes, encompassing biochemical pregnancy rate, implantation rate, clinical pregnancy rate, and early miscarriage rate. The study used single-factor analysis and multivariate logistic regression to examine the association between SARS-CoV-2 infection status, along with other relevant factors, and the early pregnancy outcomes. RESULTS: A total of 857 female patients undergoing in vitro fertilization/intracytoplasmic sperm injection treatment were analyzed. In the first stage, SARS-CoV-2 infection within 14 days after embryo transfer did not have a significant negative association with the biochemical pregnancy rate (adjusted odds ratio, 0.74; 95% confidence interval, 0.51-1.09). In the second stage, SARS-CoV-2 infection within 28 days after embryo transfer had no significant association with the implantation rate (36.6% in infected vs 44.0% in uninfected group; P=.181). No statistically significant association was found with the clinical pregnancy rate after adjusting for confounding factors (adjusted odds ratio, 0.69; 95% confidence interval, 0.56-1.09). In the third stage, SARS-CoV-2 infection within 10 weeks after embryo transfer had no significant association with the early miscarriage rate (adjusted odds ratio, 0.77; 95% confidence interval, 0.35-1.71). CONCLUSION: Our study suggests that SARS-CoV-2 infection within 10 weeks after embryo transfer may not be negatively associated with the biochemical pregnancy rate, implantation rate, clinical pregnancy rate, and early miscarriage rate in patients undergoing in vitro fertilization/intracytoplasmic sperm injection treatment. It is important to note that these findings are specific to the target population of in vitro fertilization/intracytoplasmic sperm injection patients aged 20 to 39 years, without previous SARS-CoV-2 infection, and with a body mass index of 18 to 30 kg/m2. This information offers valuable insights, addressing current concerns and providing a clearer understanding of the actual risk associated with SARS-CoV-2 infection after embryo transfer.

来源:Am J Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Li XF, Zhang YJ, Yao YL, et al. The association of post-embryo transfer SARS-CoV-2 infection with early pregnancy outcomes in in vitro fertilization: a prospective cohort study. Am J Obstet Gynecol. 2023. PMID: 38135094. doi:10.1016/j.ajog.2023.12.022

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。